Structural and functional characterization of suramin-bound MjTX-I from Bothrops moojeni suggests a particular myotoxic mechanism

Guilherme H. M. Salvador1, Thiago R. Dreyer1, Antoniel A. S. Gomes3, Walter L. G. Cavalcante1,2,3, Juliana I. dos Santos2, César A. Gandin1, Mário de Oliveira Neto1, Márcia Gallacci3 & Marcos R. M. Fontes1

Local myonecrosis is the main event resulting from snakebite envenomation by the Bothrops genus and, frequently, it is not efficiently neutralized by antivenom administration. Proteases, phospholipases A2 (PLA2) and PLA2-like toxins are found in venom related to muscle damage. Functional sites responsible for PLA2-like toxins activity have been proposed recently; they consist of a membrane docking-site and a membrane rupture-site. Herein, a combination of functional, biophysical and crystallographic techniques was used to characterize the interaction between suramin and MjTX-I (a PLA2-like toxin from Bothrops moojeni venom). Functional in vitro neuromuscular assays were performed to study the biological effects of the protein-ligand interaction, demonstrating that suramin neutralizes the myotoxic effect of MjTX-I. Calorimetric assays showed two different binding events: (i) inhibitor-protein interactions and (ii) toxin oligomerization processes. These hypotheses were also corroborated with dynamic light and small angle X-ray scattering assays. The crystal structure of the MjTX-I/suramin showed a totally different interaction mode compared to other PLA2-like/suramin complexes. Thus, we suggested a novel myotoxic mechanism for MjTX-I that may be inhibited by suramin. These results can further contribute to the search for inhibitors that will efficiently counteract local myonecrosis in order to be used as an adjuvant of conventional serum therapy.

Ophidian accidents represent an important public health problem in rural areas of Asia, Africa and Latin America, where the number of deaths caused by snakebites is higher than other neglected tropical diseases, such as dengue haemorrhagic fever, cholera, leishmaniasis, schistosomiasis and Chagas disease. These facts lead the World Health Organization1–3 to classify snakebites as a neglected disease, increasing the interest of the scientific community to study the compounds of these venoms and their eventual neutralization by specific inhibitors.

In Latin America, the Bothrops genus is responsible for approximately 85% of all ophidian accidents2,4, with myonecrosis a major event of this envenoming, which is mainly caused by the association of two proteins classes: metalloproteinases and phospholipases A2. Two main phospholipase A2 (PLA2) subclasses are often found in bothropic venoms: catalytic PLA2s and the myotoxic PLA2-like toxins. PLA2-like proteins are catalytically inactive proteins due to some natural amino acid substitutions, including Asp49Lys and Tyr28Asn, leading to Ca2+ coordination inability13,14.

The search for new inhibitors for PLA2-like proteins has been intensified in recent years15–22. Some of these known inhibitors are derived from medicinal plants (used in folk medicine, since some communities in developing countries do not have ready access to serum therapy)15–17, and others are synthetic compounds such as

1Universidade Estadual Paulista (UNESP), Instituto de Biociências, Dep. de Física e Biofísica, Botucatu, SP, Brazil.
2Universidade Federal de Minas Gerais (UFMG), Instituto de Ciências Biológicas, Dep. de Farmacologia, Belo Horizonte, MG, Brazil.
3Universidade Estadual Paulista (UNESP), Instituto de Biociências, Dep. de Farmacologia, Botucatu, SP, Brazil. Correspondence and requests for materials should be addressed to M.R.M.F. (email: fontes@ibb.unesp.br)
suramin (8,8’-[carbonylbis[iminio-3,1-phenylene(carbonylimino)bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt]). This synthetic highly charged polysulfonated compound has been clinically used in the treatment of African trypanosomiasis and onchocerciasis. Regarding its anti-ophidic activity, it has been shown that suramin is able to inhibit neuromuscular blockade induced by pre-synaptic neurotoxins, such as crotoxin and β-bungarotoxin, and to prevent muscle necrosis promoted by PLA₂-like proteins from Bothrops snake venom. It is expected that, in the near future, some of these studied inhibitors (or their modified versions) may be approved as compounds to be used as complements to the conventional serum therapy.

Important regions that can be essential for myotoxic activity in bothropic PLA₂-like proteins were recently observed. Some of these regions comprise the myotoxic site (Lys20, Lys115 and Arg118) — subsequently called the membrane docking site (MDoS) — and the membrane disruption site (MDIS) composed of the conserved residues Leu121 and Phe125. Despite these hypotheses being applied to the majority of bothropic PLA₂-like toxins, MjTX-I is an exception because its sequence does not present all the MDoS residues, and its native crystal structure exhibits a different oligomeric configuration. These factors were noted as possible factors for MjTX-I reduced myotoxicity when compared to other PLA₂-like toxins.

Recently, functional, calorimetric and structural studies with the MjTX-II/suramin complex were performed and showed the inhibition of MjTX-II myotoxic activity by suramin was due to two different mechanisms: (i) direct blockage of the MDoS and MDIS, preventing the toxin/membrane interaction and disruption; and (ii) formation of an oligomeric complex, resulting in a tetrameric configuration for which both MDoS and MDIS becomes buried (physically inaccessible), thus avoiding any possibility of toxin/membrane interaction or disruption.

In this work, we studied the binding behaviour between MjTX-I, a myotoxic PLA₂-like isolated from Bothrops moojeni venom, and the suramin molecule using a broad combination of techniques, including myographic assays, molecular dynamic simulations, dynamic light scattering (DLS), small angle X-ray scattering (SAXS), isothermal titration calorimetry (ITC) and X-ray crystallography. In the functional studies, after adding suramin to the protein solution, the MjTX-I myotoxic activity was considerably reduced in muscle preparations. Data from ITC experiments showed that interaction between suramin molecules and MjTX-I occurred, inducing protein oligomerization, a process that was also corroborated by DLS and SAXS experiments. The crystal structure of the complex MjTX-I/suramin revealed remarkable differences when compared to the native MjTX-I structure, which were mainly due to the ligand interactions. Based on the data produced and comparisons with the literature, we propose a particular myotoxic mechanism for MjTX-I and its inhibition by suramin, thus providing insights that may be very useful in the search for new components to enhance serum therapy effectiveness, particularly for bothropic snake bites.

Results

Functional assays. MjTX-I (2.5 μM) induced a time-dependent blockade of indirectly evoked twitches in mouse neuromuscular preparations (Fig. 1). Twitch amplitudes were depressed in approximately 80% after 120 minutes of toxin contact with the preparation. The time required for 50% reduction of twitch amplitudes (t1/2) was 32.5 ± 5.6 minutes (n = 4). After pre-incubation with suramin (125 μM) for 15 minutes, MjTX-I did not depress the twitch amplitudes; instead, it induced a discrete but significant facilitation of twitches starting at 75 minutes of toxin contact. Alone, suramin did not alter muscle contractions compared to the controls.

MjTX-I-suramin affinity assays. MjTX-I/suramin interactions were assessed with isothermal titration calorimetry (ITC) experiments. The titrations presented a biphasic behaviour which is characteristic of more than one binding event, with the enthalpophic component varying from endo- to exothermic (Fig. 2a). The binding isotherm was adjusted through a nonlinear regression model considering two binding events, as previously described, resulting in an interaction constant α (=[4β₁₂/β₁²] and Hill coefficient [2/(1+α−1/2)] of 0.2 and 0.6, respectively, which indicates non-identical binding or identical binding events with negative cooperativity. According to the crystallographic structure, suramin binds to both protomers of the MjTX-I homodimeric structure making different contacts in each protomer (Fig. 2b), so we considered the binding events as non-identical. For the sake of simplicity in the adjusted model, both events of suramin binding to monomers A or B of MjTX-I (MjTX-I/suramin, 1:1 molecular ratio) were considered as a general binding event, and the same was applied to the second event (MjTX-I/suramin, 2:1). Based on these assumptions, the specific dissociation constants and enthalpy changes were calculated and are summarised in Table 1.

Calorimetric data showed that suramin binds entropically in the submicromolar range to MjTX-I monomers, while the second binding event, related to dimer formation, presents 10-fold less affinity and is enthalpophically driven (Table 1). Further considerations about enthalpy changes will not be made since suramin is a highly charged polysulfonated molecule, which could lead to proton exchange and ionization, making the binding enthalpy itself different from the observed enthalpy. However, this unusual binding isotherm was not classified as an artefact since the behaviour was observed in all titrations that were performed and were repeated at least twice with each protein and the suramin dilution heat was constant in the blank titration.

Quaternary structure in solution. Dynamic light scattering (DLS) experiments showed that native MjTX-I was predominantly monomeric when dissolved at 2.5 mg.mL⁻¹ in 20 mM of ammonium bicarbonate (pH 8.5), with an unimodal molecular distribution (Pd = 13.1%) and a hydrodynamic radius (R₈₀) of 2.0 nm. On the other hand, the DLS measurements performed in the same conditions, but with pre-incubation of the protein with suramin (1:10, molecular ratio), indicated molecular oligomerization. The results presented a unimodal molecular distribution (Pd = 11.3%) with a R₈₀ of 3.4 nm, suggesting the oligomerization of MjTX-I in the presence of suramin.
SAXS experiments were performed to obtain structural information of MjTX-I in solution in the absence (native) and the presence of suramin (complexed state). Structural parameters obtained from SAXS analyses suggested that the native MjTX-I behaves as a monomer in solution (Table 2); however, the simulated scattering from

Figure 1. Effects of MjTX-I and the product of its pre-incubation with suramin on indirectly evoked twitches in mice phrenic diaphragm preparations. The ordinate represents the % of twitches relative to the initial amplitude. The abscissa indicates the time (minutes) after the addition of MjTX-I, suramin or the mixture of MjTX-I plus suramin to the organ bath. The data are grouped as means ± SEM (P < 0.05). *Indicates the point from which there was a significant difference compared with control.

Figure 2. Isothermal titration calorimetry data for the reaction of MjTX-I and suramin. Upper panel presents the titration raw data for the interaction between MjTX-I (50 μM, reaction cell) and suramin (750 μM, pipette) at 25 °C in ammonium bicarbonate (50 mM, pH 8.0). Lower panel shows the binding isotherm (squares) and the general nonlinear regression model considering two binding events (solid line).
### Table 1. Thermodynamic-binding data of MjTX-I and suramin. The estimated specific dissociation constants ($K_d$) and enthalpy changes ($\Delta H$) were determined for the binding of suramin (750 μM) to MjTX-I (50 μM) at 25 °C in ammonium bicarbonate buffer (50 mM, pH 8.0) by binding polynomials. Index 1 and 2 are related to the binding events of MjTX-I/suramin (1:1, molecular ratio) and MjTX-I/suramin (2:1), respectively.

| Parameters | Native | Monomer | Mon/Dim fit | Bound | Dimer | Tetramer |
|------------|--------|---------|-------------|-------|-------|---------|
| $R_g$ (Å) (Guinier) | 16.1 | — | 15.8 | 23.8 | — | — |
| $R_g$ (Å) | 15.9 | 14.2 | — | 24.7 | 21.6 | 26.3 |
| $D_{max}$ (Å) | 50.0 | 49.5 | — | 79.0 | 78.5 | 92.3 |
| Mol. Mass (kDa) | 9.5 | 13.7 | — | 38.8 | 27.4 | 54.8 |

### Table 2. SAXS structural parameters for the experimental data (Native and Bound protein) and for the simulated SAXS profile of the crystallographic structures (Monomer, Dimer and Tetramer).

| Parameters | Native | Monomer | Mon/Dim fit | Bound | Dimer | Tetramer |
|------------|--------|---------|-------------|-------|-------|---------|
| $R_g$ (Å) (Guinier) | 16.1 | — | 15.8 | 23.8 | — | — |
| $R_g$ (Å) | 15.9 | 14.2 | — | 24.7 | 21.6 | 26.3 |
| $D_{max}$ (Å) | 50.0 | 49.5 | — | 79.0 | 78.5 | 92.3 |
| Mol. Mass (kDa) | 9.5 | 13.7 | — | 38.8 | 27.4 | 54.8 |

the monomeric crystallographic structure (generated from PDB id: 3T0R) fitted the data with a high value of $\chi^2$ (12.8) due to an upturn of the data points in the Guinier region (Fig. 3a,b), suggesting minor oligomerization. Since the SAXS profile is an average of all conformations of the scattering particles in solution, we used Oligomer software to describe our results from the mixture of monomers/dimers in solution. Therefore, the experimental profile was better described by a 92.9%/7.1% monomeric/dimeric configuration evidenced by the decrease in the $\chi^2$ value from 12.8 (monomer fit) to 3.18 (monomer + dimer fit) (Fig. 3a,b). The insert in Fig. 3a displays a Guinier plot for both fits, confirming an increase in the radius of gyration ($R_g$) parameter (Table 2), which better describes the experimental results. In the presence of suramin, the increase in the structural and molecular weight parameters due to conformational changes (oligomerization) suggested a conformation between a dimer and a tetramer, but the dimeric and tetrameric models alone did not fit the data. Thus, Oligomer software was used to describe the experimental results by a proposed dimer/tetramer mixture and indicated the presence of 48.9% dimers and 51.1% tetramers in solution, fitting the data with a $\chi^2$ of 1.8, showing that the presence of the inhibitor favours oligomerization (Fig. 3c). The pair-distance distribution function $p(r)$ of the experimental bound SAXS data and the simulated SAXS of the dimeric and tetrameric structures are shown in Fig. 3d, demonstrating the almost 50%/50% - dimer/tetramer balance in solution.

### Crystal structure of the MjTX-I/suramin complex and its comparison with native MjTX-I.

The crystal structure of the complex MjTX-I/suramin was solved at 2.14 Å resolution and revealed an asymmetric unit (AU) composed of two protomers (identified as A and B) arranged according to the "compact dimeric" assembly in the P2$_1$2$_1$2$_1$ space group (Table 3, Fig. 4a). The final refinement converged to a $R_{work}$ value of 22.1% and an $R_{free}$ value of 24.9%, and the final model was composed of 161 solvent molecules, two PEG 4000 molecules (one located close to His48 of the monomer A and the other close to Lys7 of monomer B), and one suramin molecule (located at the hydrophobic channel, interacting with residues of both monomers) (Fig. 4c).

Comparison of the monomers of native MjTX-I and the monomers of the toxin complexed with suramin yielded an average RMSD lower than 0.8 Å, revealing that ligand binding did not affect the tertiary structure of the protein. However, its oligomeric structure is totally different (Fig. 5). While the native MjTX-I crystal structure is composed of two dimers in an "extended assembly" that gives rise to a tetrameric array, the MjTX-I/suramin complex presents a dimeric "compact assembly". Notably, the tetrameric arrangement seen with the MjTX-I/suramin complex may be a crystallization artefact due to the crystallization buffer that possessed high ionic strength. This notion is akin to the observation made in SAXS experiments reported previously, where a predominantly dimeric species similar to the "extended assembly" in the crystal structure was observed when using a low ionic strength buffer; in contrast, a monomeric species was observed when using water as solvent.

### Assessment of quaternary structure in silico.

Molecular dynamic simulations were performed to check the stability of the dimeric conformation model based on the crystal structure obtained in this work: native MjTX-I (dimeric assembly without ligands - "compact assembly") and the complex MjTX-I/suramin (dimeric assembly bound to suramin). RMSD calculations for each system presented a very different fluctuation pattern (Fig. 6). Native MjTX-I (compact assembly) presented a high RMSD - approximately 10 Å - changing its starting conformation in the first nanoseconds of simulation and acquiring an oligomeric conformation that was distinct from the initial crystallographic dimer. On the other hand, the MjTX-I/suramin complex presented a very stable RMSD fluctuation (always less than 5 Å) and maintained the quaternary conformation along the simulations.

The presence of suramin was able to stabilize the "compact dimer" of MjTX-I, inducing the toxin to a RMSD fluctuation that was very similar to those found for BbTX-I (PLA$_2$-like toxin isolated from B. jararacussu)
when simulated in similar conditions (Fig. 6). The presence of tyrosine in position 119, which is found in most PLA₂-like proteins, may play a role in dimer assembly by interactions of Tyr119 and Lys20 side chain residues, as observed in BthTX-I simulations. However, in MjTX-I, these interactions are missing due to the Tyr119Val substitution, which explains its monomeric conformation or its dimeric conformation in the "extended dimer" arrangement for particular physical-chemical conditions, as previously shown34. Therefore, the compact dimeric assembly can only be reached when MjTX-I is in the presence of suramin, since this ligand is responsible for maintenance of the dimer.

Discussion

MjTX-I paralyzing activity is neutralized by suramin. Despite PLA₂-like proteins being non-neurotoxic myotoxins, in vitro myographic assays in rodent neuromuscular preparations have been shown to be very sensitive experimental model for investigation of the basis of their membrane destabilizing activity39. This occurs because the first consequence of membrane destabilization is the collapse of the ionic gradient, which leads to cell depolarization, unexcitability and muscle paralysis4. This occurs because the first consequence of membrane destabilization is the collapse of the ionic gradient, which leads to cell depolarization, unexcitability and muscle paralysis4. Therefore, although morphological studies have clearly demonstrated that PLA₂-like proteins can induce muscle damage, functional myographic approaches revealed the early stages of this toxic effect30. Functionally, a myotoxic effect is characterized by the blockade of both indirect twitches (evoked via nerve) and direct twitches (elicited by the muscle stimulation), in contrast to a neurotoxic effect that leads to the exclusive blockade of indirect twitches. In this way, we have previously characterized the myotoxic effect of MjTX-I in a mouse phrenic-diaphragm preparation34. We showed that although it was a weaker myotoxin when compared to other PLA₂-like toxins in the experimental conditions (5 µM)34,42, MjTX-I simultaneously blocked both direct and indirect twitches. In the present work, in order to evaluate the influence of suramin upon the myotoxic effect of MjTX-I by means of myographic study, it was necessary to avoid elevated concentrations of drugs in the bath medium, which could affect the function of the neuromuscular preparation. Thus, we observed that,
at a lower concentration (2.5 µM), MjTX-I is still able to blockade the indirect contractions with a t$_{1/2}$ value (32.5 ± 5.6 minutes; n = 4), data that are not significantly different from those previously found to blockade both direct (39.5 ± 5.3 minutes; n = 4) and indirect (29.6 ± 1.7 minutes; n = 3) contractions$^{34}$. Therefore, considering these findings and the fact that the recording of indirect contractions does not require the presence of a neuromuscular blockade in the bath medium, a condition that is essential for the recording of a direct contraction, this work was based only on the recording of indirect contractions.

The present study showed that pre-incubation with suramin prevents typical paralysis induced by MjTX-I in a phrenic nerve-diaphragm muscle preparation, probably due to an inhibition of its myotoxic effect. This result is consistent with previous works that showed the ability of suramin to inhibit the neuromuscular blockade induced by PLA$_2$s-like myotoxins$^{17,22}$.

Is the particular oligomeric conformation of MjTX-I related to its lower myotoxic activity. Previous studies$^{34}$ have demonstrated that MjTX-I is a protein that can present different oligomeric states in solution. It exhibits a monomeric form when in ultra-pure water or low ionic strength buffer, but higher oligomeric states are observed in higher ionic strength buffered solutions$^{34}$. After protein purification, its behaviour in solution was investigated with DLS and SAXS experiments, either using MjTX-I in its native form and with the protein in the presence of suramin (Fig. 3). DLS assays demonstrated MjTX-I oligomerizes when suramin is added to the protein solution, since the toxin hydrophobic radius (R$_{H}$) increases from 2.0 to 3.8 nm. Indeed, SAXS assays also demonstrated that the native MjTX-I is predominantly monomeric, but in the presence of suramin, the toxin oligomerizes. These data are in agreement with ITC assays, which display a biphasic shape in thermograms, suggesting the occurrence of two phenomena: (i) suramin binding to the toxin, and (ii) protein dimerization. A similar thermogram was observed with ITC assays for the MjTX-II/suramin complex$^{22,43}$, in which suramin

| Unit cell (Å) | a = 48.7; b = 60.3; c = 102.3 |
|--------------|-----------------------------|
| Space group  | P2$_1$2$_1$2$_1$            |
| Resolution range (Å) | 51.9–2.1 (2.21–2.14)* |
| Unique reflections | 16822 (1614)* |
| Redundancy | 4.6 (4.8)* |
| Completeness (%) | 98.1 (95.44)* |
| Mean I/σ(I) | 9.6 (3.8)* |
| Wilson B-factor (Å$^2$) | 28.5 |
| Molecules in ASU | 2 |
| Matthews coefficient V$_{m}$ (Å$^3$/Da$^{-1}$) | 2.73 |
| R$_{ave}$ (%) | 12.6 (36.4)* |
| Reflections used in refinement | 16817 (1613)* |
| Reflections used for R$_{ave}$ | 850 (92)* |
| R$_{max}$ (%) | 22.1 (20.8)* |
| R$_{free}$ (%) | 24.9 (30.1)* |
| No. of non-hydrogen atoms |
| Protein | 1882 |
| Waters | 181 |
| Suramin molecules | 1 |
| PEG molecules | 2 |
| CC (suramin) | 0.924 |
| Average B-factor |
| Overall | 30.6 |
| Macromolecules | 28.7 |
| Ligands | 48.7 |
| Solvent | 40.1 |
| Ramachandran plot (%) |
| Favored | 95.4 |
| Outliers | 0.42 |
| Rotamer outliers (%) | 0.97 |
| C$_\alpha$ outliers | 0 |
| Clashscore | 8.25 |
| RMS (bonds) (Å) | 0.084 |
| RMS (angles) (°) | 0.90 |
| RMS (B-factors for bounded atoms) (Å$^2$) | 13.8 |

Table 3. X-ray data collection and refinement statistics. *Numbers in parenthesis are for the highest resolution shell.
binding to the toxin led to protein oligomerization (tetrameric conformation in this case). Thus, DLS, SAXS and ITC experiments suggested that MjTX-I dimer formation is a consequence of suramin binding. Furthermore, despite the particularities of suramin binding sites for different toxins, the suramin-induced oligomerization tendency was also observed for Ecarpholin S/suramin22,43.

Molecular dynamic simulations with MjTX-I in the “compact dimer” assembly with and without suramin also demonstrated that only the complex is stable. This result is in contrast to the assays performed with a typical PLA2-like toxin (BthTX-I), in which its native dimeric structure (“compact dimer”) is stable along with simulation. These data reinforced that the “compact dimer” conformation of MjTX-I is only stabilized by binding of the suramin inhibitor at its interface. However, as demonstrated by us previously34, the unbound structure (native MjTX-I) may eventually present higher oligomeric conformations (dimeric or tetrameric), but in this case, they are formed by the “extended dimer” assembly.

Figure 4. Crystal structure of the MjTX-I/suramin complex. (a) The overall structure of the MjTX-I/suramin complex is shown as a cartoon representation. Suramin molecule (yellow) are illustrate as stick representation. (b) Omit electron density map (coefficients 2|F_{obs}|−|F_{calc}|) corresponding to the suramin molecule is contoured at 1.2σ. (c) Interaction of suramin molecule in the MjTX-I structure. The representation of the interactions of suramin was depicted as polar contacts (broken lines) and hydrophobic contacts (arcs with radiating spokes).

Figure 5. Superposition of native MjTX-I (magenta) and MjTX-I/suramin (orange) crystal structures shown as a cartoon representation. (a) The dimeric “compact assembly” of the MjTX-I/suramin complex is highlighted. (b) Two dimeric “extended assembly” forming a tetrameric arrangement of the native MjTX-I is highlighted.
Lys69, and Lys70 (Fig. 7), which are related to the putative-MDoS suggested in the previous section. Similarly, related to the binding of the suramin molecule that hides several basic residues, particularly Arg34, Lys49, Lys53, and Lys56.

Another interesting feature observed in the MjTX-I/suramin structure is that, in contrast to other PLA$_2$-like toxins, its surface displays few basic residues exposed to the solvent (Fig. 9). Two reasons may be listed. (i) Distortion of MDiS from both monomers impairing the membrane disruption mechanism by the toxin; and (ii) surface electrostatic charge differences due to suramin binding to BstTX-II, and this fact was attributed by the authors as the main cause of toxin inhibition.

Thus, MjTX-I inhibition by the suramin may be related to two causes: (i) distortion of MDiS from both monomers impairing the membrane disruption mechanism by the toxin; and (ii) surface electrostatic charge changes of the complex that interfere with the toxin membrane dockage process (putative-MDoS is partially hidden).

**PLA$_2$-like inhibition mechanism by suramin.** Suramin has been tested as an inhibitory molecule for different PLA$_2$-like toxins, including BstTX-I from *B. jararacussu*\(^{15}\), myotoxin-II from *B. asper*\(^{17}\), MjTX-II from *B. jararaca*\(^{15}\), and MjTX-I from *B. jararaca*\(^{17,18}\). Thus, suramin may be considered as a putative-MDoS region for monomeric PLA$_2$-like toxins (described here as putative-MDoS). Indeed, as will be discussed in the next section, the suramin inhibitor binds in this region. Furthermore, the MDiS region is also on this face of the toxin, which allows the proposed myotoxic mechanism to remain possible.
Figure 7. Functional sites in monomeric structure of MjTX-I. The putative-MDoS composed by positive residues are represented as green sticks and the MDiS composed by hydrophobic residues is represented with red sticks.

Figure 8. Differences of distances from functional MDiS (red sticks) from MjTX-I/suramin and MjTX-II/FA8. MDiS distance is obtained measuring the distance between Leu121 Cβ and Phe125 Cβ. (a) Crystal structure from MjTX-I/suramin (inactive). (b) Zoomed MDiS from monomer A (7.9 Å). (c) Zoomed MDiS from monomer B (9.4 Å). (d) Dimeric structure of MjTX-II/FA8 (active). (e) Zoomed MDiS from monomer A (4.9 Å). (f) Zoomed MDiS from monomer B (5.0 Å).

B. moojeni\textsuperscript{22} and MjTX-I (present work). Crystal structures of PLA\textsubscript{2}-like toxins complexed to suramin have also been described for four different PLA\textsubscript{2}-like toxins: myotoxin-II\textsuperscript{15}, MjTX-II\textsuperscript{22}, MjTX-I and Ecarpholin S\textsuperscript{43} in order to understand the structural bases of this inhibitory mechanism.
However, the crystal structures presented remarkable differences in their oligomeric structures and on the ligand binding sites (Fig. 10). A likely reason may be the rather negative electrostatic surface potential of the ligand as well as its conformational flexibility, which allows binding to different sites of different proteins. Interestingly, despite the high sequential and structural similarity of PLA₂-like toxins, few natural mutations in these proteins may lead to different binding sites, which may also lead to oligomeric changes induced by this ligand.

Despite the diversity of the ligand-protein interactions, the oligomerization process seems to be a common feature in most PLA₂-like/suramin complexes. The dimeric structure of Ecarpholin S₄₃ presents an octameric structure when complexed to suramin; dimeric MjTX-II₂₂ oligomerizes to a tetramer in the presence of this ligand and the monomeric MjTX-I forms a dimeric arrangement in the presence of the ligand (present work). BaspTX-II is the unique exception, in which both native and complexed structures present a dimeric conformation despite the oligomeric changes observed in this structure₃₈.

The inhibitor interactions with the toxins are also distinct in these structures: the MjTX-II/suramin is complexed to two suramin molecules, which interact on the external area of each toxin monomer, being one of the sulfonated naphthyl rings close to MDoS; the other is close to the MDiS₂₂ (Fig. 10a). Suramin binds to Ecarpholin S₄₃ simultaneously to the C-terminal, N-terminal and interfacial recognition face (i-face) (Fig. 10c). In contrast, BaspTX-II/suramin and MjTX-I/suramin structures present only one inhibitor molecule, which is located in the hydrophobic channel of each considered complex. Suramin molecules establish similar interaction with both proteins, including the strictly conserved residues for PLA₂-like toxins: Gly₃₀, His₄₈, Tyr₅₂ and Lys₆₉ and other basic residues Arg₃₄, Lys₴₉, Lys₵₃ and Lys₷₀ (Fig. 10b, Sup. Fig. 2). The authors of the BaspTX-II/suramin study suggested that suramin, while interacting at this position, shifts the i-face of BaspTX-II from a positive charge region to a negatively charged region, making the protein unable to bind on the membrane. Taking into account that the suramin binds in the same regions of MjTX-I and BaspTX-II, similar methods for inhibiting the myotoxic activity for both proteins should occur.

Thus, all these structural studies demonstrated that suramin inhibits different PLA₂-like toxins by blocking their active sites (MDoS and/or MDiS), and despite the differences in the binding regions and eventual oligomeric changes suffered by the protein, this molecule is an efficient inhibitor against myotoxic effects caused by snake bites.
Concluding Remarks

*B. moojeni* snake venom seems to present interesting particularities regarding PLA₂-like myotoxicity expression. As has been demonstrated by us in the present and previous studies, MjTX-I 
34 and MjTX-II 
22,44 have peculiar myotoxic mechanisms due to differences found in their amino acid sequences that are reflected in their structures and ligand binding. Notably for MjTX-I, these structural differences lead to important reduction in its myotoxic activity. Thus, these facts need to be taken into account for the development of specific neutralizing agents against this venom. However, despite the different inhibition mechanisms by suramin against different PLA₂-like toxins, this ligand seems to be an efficient neutralizing agent for all tested PLA₂-like toxins and needs to be considered either as a potential inhibitor or as the molecular basis for new inhibitors search of local myotoxic effects caused by different ophidian accidents.

Experimental Procedures

**Toxin isolation and suramin source.** Crude venom (freeze-dried) was diluted in 50 mM ammonium bicarbonate (pH 8.0) and submitted to ion exchange chromatography. Fractions corresponding to MjTX-I were obtained by a gradient of 50 mM to 500 mM ammonium bicarbonate (pH 8.0), as previously described 
47. This fraction was submitted to a gradient of 0–66.5% acetonitrile in 0.1% trifluoroacetic acid in reverse phase chromatography to improve the sample purity. Suramin sodium salt (S2671) was obtained from Sigma Chemical Co. (St. Louis, MO, USA).

**Functional studies.** Male Swiss mice (25–30 g) were sacrificed by exsanguination after cervical dislocation. The phrenic nerve-diaphragm muscle preparations were removed and mounted vertically in a conventional organ-bath containing 15 mL of physiological solution (mM): NaCl, 135; KCl, 5; MgCl₂, 2; NaHCO₃, 15; Na₂HPO₄, 1; glucose, 11. This solution was continuously gassed with 95% O₂ and 5% CO₂ and maintained at 35 ± 1 °C. The preparation was attached to an isometric force transducer (Grass, FT03) coupled to a signal amplifier (Gould, 13–6615–50). The recordings were made on a computer through a data acquisition system.

---

Figure 10. Superposition of the MjTX-I/suramin crystal structure complex and other PLA₂-like complexed to suramin shown as a cartoon and sticks representations. (a) MjTX-I/suramin (protein in gray and suramin in orange) and MjTX-II/suramin (green). (b) MjTX-I/suramin (protein in gray and suramin in orange) and BaspTX-II/suramin (blue). (c) MjTX-I (protein in gray and suramin in orange) and Ecarpholin S/suramin (cyan).
equilibrated against a reservoir containing 500 μM PEG 4000, 0.1 M TrisHCl pH 8.5 and 0.15 M magnesium chloride. The crystal was mounted in a nylon loop and flash-cooled in a stream of nitrogen at 100 K using a synchrotron radiation source (MX2 station, LNLS – CNPEM, Campinas – SP) and a MAR CCD detector (MAR Research). The crystallographic structure was automatically refined by PHENIX package v.1.8.4 at 2.14 Å resolution using the dynamic method52 at 291 K from a mixture of 1 μL of protein/suramin solution and 1 μL reservoir solution, and this was equilibrated against a reservoir containing 500 μL with the following composition: 32% (w/v) polyethylene glycol (PEG) 4000, 0.1 M TrisHCl pH 8.5 and 0.15 M magnesium chloride.

Small Angle X-ray Scattering. Small angle X-ray scattering (SAXS) data were collected at the Brazilian Synchrotron Light Laboratory (LNLS – CNPEM, Campinas – SP) using the SAXS2 beamline. The wavelength of the incident beam radiation was set to λ = 1.325 Å, and the sample-detector distance was adjusted to 1007 mm, resulting in a scattering vector ranging from 0.013 Å⁻¹ < q < 0.319 Å⁻¹ (q = 4π sinθ/λ, where θ is the scattering angle). The scattering pattern was recorded in a MAR CCD detector (MAR Research). Data for MjTX-I were collected at 1 and 5 mg.mL⁻¹ dissolved in 20 mM of ammonium bicarbonate (pH 8.5) in the absence and presence of suramin (MjTX-I:suramin 1:10) respectively, to evaluate changes in the protein oligomerization state due to the presence of the inhibitor. SAXS patterns were corrected for the detector responses and scaled by the incident beam intensity and sample absorption. The background scattering curve was subtracted from the corresponding sample scattering. Integration of the bi-dimensional SAXS patterns were performed using Fit2D software48.

Guinier analysis of the radius of gyration (Rg) was performed using Primus software57. Fitting of the experimental data and evaluation of the pair-distance distribution function p(r) were conducted using Gnom software49. Molecular weight and oligomerization state evaluations were conducted using SASSMoW50. Crysol software51 was used to simulate the scattering profile of crystallographic structures and to evaluate their structural parameters, and Oligomer software52 was used to evaluate mixtures of oligomeric states, determining the percentage of each population in solution.

Crystallographic and X-ray data collection. MjTX-I purified fraction was concentrated up to 10 mg.mL⁻¹ in 20 mM ammonium bicarbonate (pH 8.5), and suramin was added to the solution in order to obtain a molar ratio of 1:10. Crystals of the complex MjTX-I/suramin were obtained with the hanging drop vapour-diffusion method52 at 291 K from a mixture of 1 μL of protein/suramin solution and 1 μL reservoir solution, and this was equilibrated against a reservoir containing 500 μL with the following composition: 32% (w/v) polyethylene glycol (PEG) 4000, 0.1 M TrisHCl pH 8.5 and 0.15 M magnesium chloride.

X-ray diffraction data were collected from a single MjTX-I/suramin crystal at a wavelength of 1.325 Å (at 100 K) using a synchrotron radiation source (MX2 station, LNLS – CNPEM, Campinas – SP) and a MAR CCD detector (MAR Research). The crystal was mounted in a nylon loop and flash-cooled in a stream of nitrogen at 100 K with no cryoprotectant. The crystal-to-detector distance was 80 mm, and an oscillation range of 1° was used, resulting in the collection of 121 frames. Data were processed to 2.14 Å resolution using the HKL2000 program package53.

Structure determination and refinement. The Molecular Replacement Method using the PHASER program54 from PHENIX package v.1.8.4 and the monomer A atomic coordinates of the native MjTX-I structure (PDB access code 3TOR) as the search model. The modelling process was performed using the COOT v.0.7.1 program55, which was also used to add PEG 4000, solvent molecules and suramin molecules to the model. The crystallographic structure was automatically refined by PHENIX package v.1.8.4. Due to the lack of electron densities, amino acid side chains Glu86 and Lys69 in monomer A and Lys128 in monomer B were not modelled. PHENIX package v.1.8.4 was used to check the general quality of the final model. Refinement statistics and other information are shown in Table 3. The coordinates of the MjTX-I/suramin structure was deposited in the Protein Data Bank (PDB) under the identification code (PDB ID code): 6CE2.

Comparative analysis. The crystal structures of the MjTX-I/suramin complex (this work), native MjTX-I (PDB id: 3TOR)54, MjTX-II/suramin (Myotoxin II isolated from Bothrops moojeni venom - PDB id: 4YV5)53, BaspTX-II/suramin (Myotoxin II isolated from Bothrops asper venom - PDB id: 1Y4L)53 and Echaperolin S/
suramin (Myotoxic Ser49-PLA2, isolated from Echis carinatus venom - PDB id: 3BJW) were compared using the Coot v0.7.1 program. Structural figures were generated using the PyMOL v1.3 program, LigPilot v1.4.5 and images containing electrostatic surfaces were generated using the Chimera v.1.9 program.

**Molecular-dynamics simulations.** MJTX-I and MJTX-I/suramin crystallographic structures were submitted to MD simulations using GROMACS (Groningen Machine for Chemical Simulation) v. 5.0.6 under the GROMOS 54A7 force field and the simple point charge (SPC) water model. Before proceeding to the MD simulations, the protonation states of the MJTX-I were calculated using PROPKA4 and set to a pH value of 8.0. Each system was placed in a triclinic box with a distance of 4 Å from the farthest atom and then solvated and equilibrated with NaCl 100 mM. The steepest descent algorithm was used to minimize all systems energy below 100kJ/mol/Å, and then restraints in MJTX-I and suramin were performed under a V-rescale weak temperature coupling thermostat at 310 K for 1 ns, followed by a 1-ns step of isobaric simulation (1 bar) under a Berendsen pressure coupling barostat using position restraints. Subsequently, 100 ns of unrestrained MD simulations were performed under a Nose–Hoover thermostat and Parrinello–Rahman barostat.

The suramin topology was built using an ATB (Automated Topology Builder v. 2.2) online server. The resulting topologies were carefully analysed, and all charges were fixed based on the force field parameters that were used, as previously suggested.

**References**

1. Williams, D. *et al.* The Global Snake Bite Initiative: an antidote for snake bite. *Lancet* 375, 89–91 (2010).
2. Kasturiratne, A. *et al.* The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenomtion and deaths. *PLoS Med* 5, e218 (2008).
3. Harrison, R. A., Hargreaves, A., Wagstaff, S. C., Faragher, B. & Laloo, D. G. Snake envenoming: a disease of poverty. *PLoS Negl Trop Dis* 3, e569 (2009).
4. Gutierrez, J. M. & Lomonte, B. Phospholipase A2 myotoxins from Bothrops snake venoms. *Toxicon* 33, 1405–1424 (1995).
5. Oliveira, A. K. *et al.* New insights into the structural elements involved in the skin haemorrhage induced by snake venom metalloproteinases. *Thromb Haemost* 104, 485–497 (2010).
6. Gutierrez, J. M. & Ownby, C. L. Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity. *Toxicon* 42, 915–931 (2003).
7. Harris, J. B. & Cullen, M. J. Muscle necrosis caused by snake venoms and toxins. *Electron Microsc Rev* 3, 183–211 (1990).
8. Lomonte, B., Angulo, Y. & Calderon, L. An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. *Toxicon* 42, 885–901 (2003).
9. Gutierrez, J. M., Rucavado, A., Escalante, T. & Diaz, C. Hemorrhage induced by snake venom metalloproteinases: biochemical and biophysical mechanisms involved in microvascular damage. *Toxicon* 45, 997–1001 (2005).
10. Gutierrez, J. M., Ponce-Soto, L. A., Marangoni, S. & Lomonte, B. Systemic and local myotoxicity induced by snake venom group II phospholipases A2: comparison between crototoxin, crototoxin B and a Lys49 PLA2 homologue. *Toxicon* 51, 80–92 (2008).
11. Mora, J., Mora, R., Lomonte, B. & Gutierrez, J. M. Effects of Bothrops asper snake venom on lymphatic vessels: insights into a hidden aspect of envenomation. *PLoS Negl Trop Dis* 2, e318 (2008).
12. Gutierrez, J. M., Rucavado, A., Chaves, F., Diaz, C. & Escalante, T. Experimental pathology of local tissue damage induced by *Bothrops asper* snake venom. *Toxicon* 54, 958–975 (2009).
13. Holland, D. R. *et al.* The crystal structure of a lysine 49 phospholipase A2 from the venom of the cottonmouth snake at 2.0 Å resolution. *J Biol Chem* 265, 17649–17656 (1990).
14. Fernandes, C. A. *et al.* Comparison between apo and complexed structures of bothropothorax-I reveals the role of Lys122 and Ca2+-binding loop region for the catalytically inactive Lys49 PLA2. *J Struct Biol* 171, 31–43 (2010).
15. Murakami, M. T. *et al.* Inhibition of myotoxic activity of *Bothrops asper* myotoxin II by the anti-trypanosomal drug suramin. *J Mol Biol* 350, 416–426 (2005).
16. Murakami, M. T. *et al.* Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues. *Toxicon* 49, 378–387 (2007).
17. de Oliveira, M. R. *et al.* Antagonism of myotoxic and paralyzing activities of *Bothrops asper* venom by suramin. *Toxicon* 42, 373–379 (2003).
18. Ticli, F. K. *et al.* Rosmarinic acid, a new snake venom phospholipase A2 inhibitor from *Cordia verbenacea* (Boraginaceae): antiserum action potentiation and molecular interaction. *Toxicon* 46, 318–327 (2005).
19. Lomonte, B., Leon, G., Angulo, Y., Rucavado, A. & Nunez, V. Neutralization of *Bothrops asper* venom by antibodies, natural products and synthetic drugs: contributions to understanding snakebite envenoming and their treatment. *Toxicon* 54, 1012–1028 (2009).
20. Marcussi, S. *et al.* Snake venom phospholipase A2 inhibitors: medicinal chemistry and therapeutic potential. *Curr Top Med Chem* 7, 743–756 (2007).
21. Dos Santos, J. I. *et al.* Structural and functional studies of a bothropic myotoxin complexed to rosmarinic acid: new insights into Lys49-PLA2, inhibition. *PLoS One* 6, e28521 (2011).
22. Salvador, G. H. *et al.* Structural and functional evidence for membrane docking and disruption sites on phospholipase A2-like proteases revealed by complexation with the inhibitor suramin. *Acta Crystallogr D Biol Crystallogr* 71, 2066–2078 (2015).
23. Soares, A. M. *et al.* Medicinal plants with inhibitory properties against snake venoms. *Curr Med Chem* 12, 2625–2641 (2005).
24. Samy, R. P., Thwin, M. M., Gopalakrishnan, P. & Ignacimuthu, S. Ethnobotanical survey of folk plants for the treatment of snakebites in Southern part of Tamilnadu, India. *J Ethnopharmacol* 115, 302–312 (2008).
25. Burch, T. A. & Ashburn, L. L. Experimental therapy of onchocerciasis with suramin and hetrazan; results of a three-year study. *Am J Trop Med Hyg* 31, 617–623 (1951).
26. Williamson, J. & Desowitz, R. S. Prophylactic activity of suramin complexes in animal trypanosomiasis. *Nature* 177, 1074–1075 (1956).
27. Lin-Shiau, S. Y. & Lin, M. J. Suramin inhibits the toxic effects of presynaptic neurotoxins at the mouse motor nerve terminals. *Eur J Pharmacol* 382, 75–80 (1999).
28. Pathi, B., Harvey, A. L. & Rowan, E. G. Suramin inhibits the early effects of PLAs, neurotoxins at mouse neuromuscular junctions: A twitch tension study. *J Venom Res* 26, 6–10 (2011).
29. Arruda, E. Z., Silva, N. M., Moraes, R. A. & Melo, P. A. Effect of suramin on myotoxicity of some crotalid snake venoms. *Br J Med Res* 35, 723–726 (2002).
30. dos Santos, J. I., Soares, A. M. & Fontes, M. R. Comparative structural studies on Lys49 phospholipases A2 from *Bothrops* genus reveal their myotoxic site. *J Struct Biol* 167, 106–116 (2009).
31. Fernandes, C. A. *et al.* Structural bases for a complete myotoxic mechanism: crystal structures of two non-catalytic phospholipases A2-like from *Bothrops brazili* venom. *Biochim Biophys Acta* 1834, 2772–2781 (2013).
32. Arni, R. K. & Ward, R. J. Phospholipase A2 - a structural review. *Toxicon* 34, 827–841 (1996).
Acknowledgements

Funding was provided by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Author Contributions

G.H.M.S. performed D.L.S., crystallographic and structural comparative analyses under supervision of M.R.M.F. T.R.D. performed I.T.C. assays under supervision of M.R.M.F. A.A.S.G. performed molecular dynamics simulations under supervision of M.R.M.F. W.L.G.C. performed functional assays under supervision of M.G. C.A.G. performed S.A.X.S. experiments under supervision of M.O.N. M.R.M.F., J.I.S. and G.H.M.S. designed, analysed the experiments and wrote the manuscript with inputs of other authors.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28584-7.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018